Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis

Li, Qinchen; Wang, Zhize; Yi, Jiahe; Shen, Haixiang; Yang, Zitong; Yan, Libin; Xie, Liping

doi:10.1016/j.tranon.2021.101145

Cited by 9 publications

(8 citation statements)

References 52 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment options for patients with CRPC are severely limited [ 5 , 37 , 39 ], and constitutively active AR splice variants, especially AR-v7, pose a significant challenge [ 52 ]. Our in vitro findings suggested that the above two orally available pharmaceutical agents may pre-sensitize CRPC cells and enhance the tumor-eliminating ability of FUS by suppressing crucial pro-survival signaling pathways.…”

Section: Discussionmentioning

confidence: 99%

“…Our in vitro findings suggested that the above two orally available pharmaceutical agents may pre-sensitize CRPC cells and enhance the tumor-eliminating ability of FUS by suppressing crucial pro-survival signaling pathways. In addition to AR, both NF-κB and Akt signaling pathways play central roles in CRPC cell proliferation and metastasis, via pro-inflammatory signaling, and production of cytokines, chemokines and adhesion molecules [ 35 , 52 , 53 ]. In the absence of androgen, CRPC cells rely on these alternative pro-survival mechanisms to maintain their uncontrolled proliferation and metastatic behavior.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pre-Exposure to Stress-Inducing Agents Increase the Anticancer Efficacy of Focused Ultrasound against Aggressive Prostate Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Despite the initial success in treatment of localized prostate cancer (PCa) using surgery, radiation or hormonal therapy, recurrence of aggressive tumors dictates morbidity and mortality. Focused ultrasound (FUS) is being tested as a targeted, noninvasive approach to eliminate the localized PCa foci, and strategies to enhance the anticancer potential of FUS have a high translational value. Since aggressive cancer cells utilize oxidative stress (Ox-stress) and endoplasmic reticulum stress (ER-stress) pathways for their survival and recurrence, we hypothesized that pre-treatment with drugs that disrupt stress-signaling pathways in tumor cells may increase FUS efficacy. Using four different PCa cell lines, i.e., LNCaP, C4-2B, 22Rv1 and DU145, we tested the in vitro effects of FUS, alone and in combination with two clinically tested drugs that increase Ox-stress (i.e., CDDO-me) or ER-stress (i.e., nelfinavir). As compared to standalone FUS, significant (p < 0.05) suppressions in both survival and recurrence of PCa cells were observed following pre-sensitization with low-dose CDDO-me (100 nM) and/or nelfinavir (2 µM). In drug pre-sensitized cells, significant anticancer effects were evident at a FUS intensity of as low as 0.7 kW/cm2. This combined mechanochemical disruption (MCD) approach decreased cell proliferation, migration and clonogenic ability and increased apoptosis/necrosis and reactive oxygen species (ROS) production. Furthermore, although activated in cells that survived standalone FUS, pre-sensitization with CDDO-me and/or nelfinavir suppressed both total and activated (phosphorylated) NF-κB and Akt protein levels. Thus, a combined MCD therapy may be a safe and effective approach towards the targeted elimination of aggressive PCa cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pre-Exposure to Stress-Inducing Agents Increase the Anticancer Efficacy of Focused Ultrasound against Aggressive Prostate Cancer Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, knockdown of YAP1 and PAK2 both reduced cell colony formation and cell invasion activity also suggested an important factor in CRPC invasion (19). Similarly, AR-V7 positivity associated with a higher bone, or any site, metastasis in CRPC (16). Moreover, knockdown of EpCAM contributed to reduced invasion in PC-3, DU145, and C4-2B cells (32).…”

Section: Crpc Invasion and Metastasismentioning

confidence: 94%

Emerging Proteins in CRPC: Functional Roles and Clinical Implications

Kong

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common cancer in men in the western world, but the lack of specific and sensitive markers often leads to overtreatment of prostate cancer which eventually develops into castration-resistant prostate cancer (CRPC). Novel protein markers for diagnosis and management of CRPC will be promising. In this review, we systematically summarize and discuss the expression pattern of emerging proteins in tissue, cell lines, and serum when castration-sensitive prostate cancer (CSPC) progresses to CRPC; focus on the proteins involved in CRPC growth, invasion, metastasis, metabolism, and immune microenvironment; summarize the current understanding of the regulatory mechanisms of emerging proteins in CSPC progressed to CRPC at the molecular level; and finally summarize the clinical applications of emerging proteins as diagnostic marker, prognostic marker, predictive marker, and therapeutic marker.

show abstract

“…The most well-described AR-V is still AR-V7. In CRPC, a recent meta-analysis revealed that AR-V7-positive is linked to greater ECOG performance, metastatic spread, higher Gleason scores, and worse pain management [ 62 ].…”

Section: Molecular Events On Resistance Mechanisms To Ar Signaling Pa...mentioning

confidence: 99%

Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?

Pozas

Rodríguez

Albarrán

et al. 2022

Cancers

View full text Add to dashboard Cite

The androgen signaling pathway is the cornerstone in the treatment of high risk or advanced prostate cancer patients. However, in recent years, different mechanisms of resistance have been defined in this field, limiting the efficacy of the currently approved antiandrogen drugs. Different therapeutic approaches are under research to assess the role of combination therapies against escape signaling pathways or the development of novel antiandrogen drugs to try to solve the primary or acquired resistance against androgen dependent or independent pathways. The present review aims to summarize the current state of androgen inhibition in the therapeutic algorithm of patients with advanced prostate cancer and the mechanisms of resistance to those available drugs. In addition, this review conducted a comprehensive overview of the main present and future research approaches in the field of androgen receptor inhibition to overcome these resistances and the potential new drugs under research coming into this setting.

show abstract

Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis

Cited by 9 publications

References 52 publications

Pre-Exposure to Stress-Inducing Agents Increase the Anticancer Efficacy of Focused Ultrasound against Aggressive Prostate Cancer Cells

Pre-Exposure to Stress-Inducing Agents Increase the Anticancer Efficacy of Focused Ultrasound against Aggressive Prostate Cancer Cells

Emerging Proteins in CRPC: Functional Roles and Clinical Implications

Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?

Contact Info

Product

Resources

About